Pure Global
NCT05133999

Iron and Retinopathy of Prematurity (ROP)

Iron, Transferrin and Retinopathy of Prematurity (ROP): Towards New Pathophysiological Mechanisms.
Assistance Publique - Hôpitaux de Paris·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Retinopathy of Prematurity
Drug/Device/Intervention
Plasma determination of iron, transferrin and ferritin
Study type
Observational
Intervention type
biological
Sponsor & location
Primary sponsor
Assistance Publique - Hôpitaux de Paris
Location
Paris,Paris,Paris, France
Timeline & enrollment
Phase
N/A
Start date
Apr 28, 2022
End date
Sep 01, 2024
Enrollment
175 participants
Primary outcome

ROP screening,Levels of transferrin saturation in plasma at 1 week of life

Summary

The purpose of this study is to determine whether increased transferrin saturation in plasma
 (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP
 development and severity.
 
 Preterm infants born at 31 week's post-menstrual age (PMA) or ≤1250g of birth weight will be
 included. Iron parameters in plasma will be measured during the first month of life.
 Retinopathy of prematurity (ROP) will be screened as currently recommended. The relationship
 between plasma iron parameters and ROP development and/or severity will be established.

ICD-10 classifications
Retinopathy of prematurityOther proliferative retinopathyBackground retinopathy and retinal vascular changesDiabetic retinopathyRetinal disorder, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05133999
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05133999 through Pure Global AI's free database. This phase not specified trial is sponsored by Assistance Publique - Hôpitaux de Paris and is currently Recruiting. The study focuses on Retinopathy of Prematurity. Target enrollment is 175 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.